83% of Users Want the FDA to Make Peptides More Accessible

A new survey suggests Americans want a clearer, medically supervised way to access popular peptides. 

Among 2,491 peptide-aware U.S. adults surveyed by Hone Health in May 2026, 83% support allowing licensed compounding pharmacies to produce popular peptides with a physician’s prescription. 

The finding comes days before an FDA advisory committee meets to consider whether seven widely used peptides — BPC-157, TB-500, KPV, MOTS-c, Emideltide (DSIP), Semax, and Epitalon — should become eligible for compounding. The outcome could determine whether consumers can access compounded versions through a physician rather than relying on products sold outside traditional, authorized medical channels.

“Right now, most people can’t get these compounds in a safe, controlled manner, so they get them however they can,” says Abid Husain, M.D., a triple-board-certified physician specializing in peptide therapy who will be presenting at the meeting. “And that means putting themselves at exceptional risk.”

About the Expert

Abid Husain, M.D., is a triple-board-certified physician specializing in peptide therapy.

What Is the FDA Reviewing at the July 2026 Peptide Meeting? 

The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which ingredients compounding pharmacies can use to make prescription medications. 

At its July 23 and 24 meeting, the committee will consider whether the seven peptides should be added to the 503A Bulks List. Inclusion would allow licensed pharmacists and physicians to use them in patient-specific compounded prescriptions. 

PCAC will make recommendations to the FDA, which will consider the committee’s advice as well as public comments before making a final decision. 

If the FDA moves these peptides to the 503A Bulks List, it doesn’t mean that they are approved as drugs. But it would allow physicians to prescribe them — both for the conditions discussed during the meeting, such as ulcerative colitis in the case of BPC-157, but also other uses when medically appropriate, such as athletic or cognitive performance.¹

“I’m anticipating we’ll know where these peptides sit in the recategorization by November or December,” Husain says.

Peptides Under FDA Review in July 2026

The conditions in the third column are uses the PCAC is considering as part of its review. The final column reflects other potential applications already popular among peptide users.

Hone Survey Data Show People Are Already Using These Peptides

Hone’s survey confirms that the peptides on the FDA’s agenda are already part of many American’s wellness routines, despite the lack of a clear prescription pathway.

Percent of Survey Respondents Taking the Peptides Being Reviewed

• BPC-157: 18%
• TB-500: 16%
• Wolverine Stack (BPC-157 + TB-500): 18%
• Emideltide / DSIP: 16.7%
• Semax: 16%
• Epitalon: 14%
• KPV: 11.5%
• MOTS-c: 9%

The peptides under review are often sold online with labels such as “for research use only,” meaning they are intended for laboratory research rather than human use. Gray-market peptides may contain the wrong concentration, impurities, contaminants, or a different substance altogether, Husain says. Consumers may also be left to determine dosing and monitor side effects on their own.

“If someone experiences benefits or side effects, we don’t know if they’re from the peptide or because of impurities, endotoxins, or anything else that could be in there,” Husain says.

Those risks haven’t eliminated demand, but they may be discouraging some prospective users. Per Hone’s survey, 39% of peptide-curious Americans said FDA reclassification would be the single biggest reason they would try peptides or use them more often.

What Would Physician-Supervised Access Change?

If FDA adds any of the peptides to the 503A Bulks List, eligible compounding pharmacies could prepare them for individual patients with valid prescriptions.

Licensed compounding pharmacies add multiple safeguards. Licensed compounding pharmacies typically:^{2 3}

• source pharmaceutical-grade active ingredients from qualified suppliers
• prepare medications in sterile facilities
• follow quality-assurance procedures
• employ licensed pharmacists
• operate under state oversight and FDA inspection

That oversight also matters to consumers. In Hone’s survey, 9 in 10 respondents said physician involvement would significantly or somewhat increase their trust in peptides.

Doctors could screen patients for contraindications, prescribe appropriate doses, and monitor treatment over time. They could adjust therapy based on a patient’s response instead of leaving people to navigate peptide use through Reddit, AI, and other unqualified sources.

“There’s a responsibility that physicians and other practitioners bring to using these medications,” Husain says. “They have to be used in a therapeutic manner with attention to the indications, effects, and side effects.”

As soon as the FDA eases restrictions on peptides, Hone will offer them. Want early access to peptides at Hone? Join the waitlist. 

The Bottom Line

A Hone Health survey suggests many people are already using peptides the FDA is considering reclassifying. Both current and prospective users say they’d prefer to access them through licensed compounding pharmacies with physician oversight. Reclassification could move demand from the gray market into personalized medical care.

About the author

Brittany Risher Englert is a content strategist, editor, and writer with more than 15 years of experience. She specializes in creating health and wellness content for brands and media companies such as Levels, Marble, K Health, and Conde Nast and Hearst publications.